Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

  • Adam Feuerstein

By Adam Feuerstein Nov. 7, 2019

Reprints
Cambridge: Sarepta
Ruby Wallau for STAT

Sarepta Therapeutics CEO Doug Ingram is taking the high road.

In remarks Thursday on a quarterly earnings call, Ingram refused to criticize the Food and Drug Administration for rejecting Sarepta’s Duchenne muscular dystrophy drug Vyondys 53.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Dope Sick: A harrowing story of best friends, addiction…
Dope Sick: A harrowing story of best friends, addiction — and a stealth killer
FDA report details problems at Global Pharma plant involved…
FDA report details problems at Global Pharma plant involved in eye drop recall
3 keys to successful biopharma-academia drug development collaborations
3 keys to successful biopharma-academia drug development collaborations
Listen: Biotech’s monkey shortage, the broken generics market, &…
Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

Comments are closed.

Recommended Stories